Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-29
2008-01-29
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S252050, C514S381000, C544S366000, C548S255000, C548S252000, C548S254000
Reexamination Certificate
active
07323480
ABSTRACT:
The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders.
REFERENCES:
patent: 2711424 (1955-06-01), Suter et al.
patent: 3158645 (1964-11-01), Newcer et al.
patent: 3378582 (1968-04-01), Bolhofer
patent: 3444299 (1969-05-01), Woo et al.
patent: 3469009 (1969-09-01), Klingbail
patent: 3517050 (1970-06-01), Bolhofer
patent: 3517051 (1970-06-01), Bolhofer
patent: 3536809 (1970-10-01), Applezweig
patent: 3546229 (1970-12-01), Griot
patent: 3558778 (1971-01-01), Klingbail
patent: 3564042 (1971-02-01), Griot
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3658829 (1972-04-01), Nakamura et al.
patent: 3674836 (1972-07-01), Creger
patent: 3707549 (1972-12-01), Mils
patent: 3816446 (1974-06-01), Bolhofer
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3860628 (1975-01-01), Shuman
patent: 3876791 (1975-04-01), Hubbard et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3923855 (1975-12-01), Shuman
patent: 3953490 (1976-04-01), Shuman
patent: 4001268 (1977-01-01), Kovar et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4067996 (1978-01-01), Najer et al.
patent: 4072754 (1978-02-01), Schacht et al.
patent: 4125729 (1978-11-01), Trust et al.
patent: 4146623 (1979-03-01), Parker
patent: 4168385 (1979-09-01), Trust et al.
patent: 4250191 (1981-02-01), Edwards
patent: 4338330 (1982-07-01), Gillet et al.
patent: 4508882 (1985-04-01), Yoshida et al.
patent: 4528311 (1985-07-01), Beard et al.
patent: 4532135 (1985-07-01), Edwards
patent: 4714762 (1987-12-01), Hoefle et al.
patent: 4863802 (1989-09-01), Moore et al.
patent: 4891396 (1990-01-01), Aver et al.
patent: 4910211 (1990-03-01), Imamura et al.
patent: 4933367 (1990-06-01), Wolff et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5041640 (1991-08-01), Creger
patent: 5132429 (1992-07-01), Narita et al.
patent: 5284599 (1994-02-01), Iwaki et al.
patent: 5476946 (1995-12-01), Linker et al.
patent: 5496826 (1996-03-01), Watson et al.
patent: 5500332 (1996-03-01), Vishwakarma et al.
patent: 5516914 (1996-05-01), Winter et al.
patent: 5518625 (1996-05-01), Priegnitz et al.
patent: 5554759 (1996-09-01), Vishwakarma
patent: 5700819 (1997-12-01), Aotsuka et al.
patent: 5716987 (1998-02-01), Wille
patent: 5766834 (1998-06-01), Chen et al.
patent: 5859501 (1999-01-01), Chi
patent: 5874431 (1999-02-01), Stevens et al.
patent: 5883124 (1999-03-01), Samid
patent: 5942626 (1999-08-01), Winter et al.
patent: 6013659 (2000-01-01), Goldfarb et al.
patent: 6034246 (2000-03-01), Stevens et al.
patent: 6037393 (2000-03-01), Okumura et al.
patent: 6184235 (2001-02-01), Connor et al.
patent: 6201000 (2001-03-01), Luther et al.
patent: 6248768 (2001-06-01), Yamada et al.
patent: 6262118 (2001-07-01), Luskey et al.
patent: 6417212 (2002-07-01), Brooks et al.
patent: 6506747 (2003-01-01), Betageri et al.
patent: 6610696 (2003-08-01), Brooks et al.
patent: 6613802 (2003-09-01), Luskey et al.
patent: 6624194 (2003-09-01), Luskey et al.
patent: 6646004 (2003-11-01), Luskey et al.
patent: 6670395 (2003-12-01), Wille
patent: 6710063 (2004-03-01), Chao et al.
patent: 6875782 (2005-04-01), Cheng et al.
patent: 2003/0203947 (2003-10-01), Chao et al.
patent: 2003/0207915 (2003-11-01), Cheng et al.
patent: 2003/0207916 (2003-11-01), Cheng et al.
patent: 2003/0207924 (2003-11-01), Cheng et al.
patent: 2003/0220399 (2003-11-01), Luskey et al.
patent: 2003/0225158 (2003-12-01), Auerbach et al.
patent: 2004/0019090 (2004-01-01), Brooks et al.
patent: 2004/0039053 (2004-02-01), Luskey et al.
patent: 2004/0077659 (2004-04-01), Oliver
patent: 2004/0204472 (2004-10-01), Briggs
patent: 2005/0033084 (2005-02-01), Daugs
patent: 0 077 938 (1983-05-01), None
patent: 0 105 494 (1984-04-01), None
patent: 0 306 708 (1989-03-01), None
patent: 1 162 196 (2001-12-01), None
patent: 1371650 (2003-12-01), None
patent: 1403309 (1975-08-01), None
patent: 49-51243 (1974-05-01), None
patent: 49-51246 (1974-05-01), None
patent: 53-015325 (1978-02-01), None
patent: 53-71071 (1978-06-01), None
patent: 60-109578 (1986-06-01), None
patent: WO 97/28149 (1997-08-01), None
patent: WO 98/23252 (1998-06-01), None
patent: WO 98/04955 (1998-11-01), None
patent: WO 99/11627 (1999-03-01), None
patent: WO 99/04815 (1999-04-01), None
patent: WO 00/35886 (2000-06-01), None
patent: WO 00/74666 (2000-12-01), None
patent: WO 03/074051 (2003-09-01), None
patent: WO 03/080545 (2003-10-01), None
patent: WO 2005/115383 (2005-12-01), None
patent: WO 96/26207 (2006-08-01), None
Aronow, W.S., et al., “Effect of halofenate on serum lipids”, Clin. Pharmacol. Ther., 1973, vol. 14, No. 3, pp. 358-365.
Aronow, W.S., et al., “Halofenate: An Effective Hypolipemia- and Hypouricemia- Inducing Drug”, Current Therapeutic Research, 1973, vol. 15, No. 12, pp. 902-906.
Babler, J., et al., “Reduction of Acid Chlorides with Sodium Borohydride in N, N-Dimethylformamide: Nature of the Reaction Intermediate and a Method for it's Conversion to the Corresponding Aldehyde with Minimal Alcohol Formation,” Tetrahedron Letters, 1981, vol. 22, pp. 11-14.
Bardin, C.W., eds., Current Therapy in Endocrinology and Metabolism, 6th Edition, Mosby—Year Book, Inc., St. Louis, MO, 1997, pp. 509-519.
Barrett-Conner, “Epidemology, Obesity, and Non-Insulin-Dependent Diabetes Mellitus”, Epidemol. Rev., 1989, vol. 11, pp. 172-181.
Bassett, D.R., et al., “Effects of halofenate and probenecid in serum lipids and uric acid in hyperlipidemic, hyperuricemic adults,” Clin. Pharmacol. Ther. 1977, vol. 22, No. 3, pp. 340-351.
Bell, G., et al., “Glucokinase Mutations, Insulin secretion, and Diabetes Mellitus,” Annu. Rev. Physiol., 1996, vol. 58, No. pp. 171-187.
Berkow, R., Chapter 94, “Disorders of Carbohydrate Metabolism,” The Merck Manual of Diagnosis and Therapy 15th ed.,Merck Sharp&Dohme Research Laboratories, 1987, pp. 1069-1072.
Bluestone, R., et al., “HalofenateIts Selection and Trial as a Primary Uricosuric Agen”t, Arthritis Rheum., 1975, vol. 18, pp. 859-862.
Brooks, D. A., et al., “Design and Synthesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy} propionic Acids: A New Class of Dual PPARaly Agonists,” J. Med. Chem., 2001, vol. 44, No. 13, 2061-2064.
Chaikin, Saul W., et al., “Reduction of Aldehydes, Ketones and Acid Chlorides by Sodium Borohydride,” J. Amer. Chem. Soc., 1949 vol. 71, pp. 122-127.
Chiasson, J., et al., “The Efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependent Diabetes Mellitus,” Annals of Intern. Med., 1994 vol. 121, No. 12, pp. 928-935.
Coniff, R., et al., “Acarbose: A Review of US Clinical Experience,” Clinical Therapeutics, 1997, vol. 19, No. 1, pp. 16-26.
Coniff, R., et al., “Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus,” The American Journal of Medicine, 1995, vol. 98, pp. 443-451.
Dorfler, H., et al., “Primãrer Verteilungsraum und Plasmahalbwertszeit von intravenous verabreichtem Insulin,” Med. Poliklinik Univ. Muchen, vol. 82, pp. 1297-1299.
Dressel, U., et al., “The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells,” Mol. Endocrinol. 2003, vol. 17, No. 12, pp. 2477-2
Cheng Peng
Gregoire Francine M.
Ma Jingyuan
Rakhmanova Vera A.
Zhao Zuchun
Anderson Rebecca
Chu Yong
Metabolex Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Substituted triazoles as modulators of PPAR and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted triazoles as modulators of PPAR and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted triazoles as modulators of PPAR and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2809656